Impact of MIC Range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the Ceftolozane in Vivo pharmacokinetic/pharmacodynamic target

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 6311-6314

  Lepak, A J ^a   Reda, A ^a   Marchillo, K ^a   Hecker, J V ^a   Craig, W A ^a   Andes, D ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOLOZANE; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE;

EID: 84907916926     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAc.03572-14     Document Type: Article

References (24)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12. http://dx.doi.org/10.1086/595011.
2. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. 2013. Antimicrobialresistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect. Control Hosp. Epidemiol. 34:1-14. http://dx.doi.org/10.1086/668770.
3. Klevens RM, Edwards JR, Richards CL, Jr, Horan TC, Gaynes RP, Pollock DA, Cardo DM. 2007. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 122:160-166.
4. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2011. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob. Agents Chemother. 55:2390-2394. http://dx.doi.org/10.1128/AAC.01737-10.
5. Bulik CC, Christensen H, Nicolau DP. 2010. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob. Agents Chemother. 54:557-559. http://dx.doi.org/10.1128/AAC.00912-09.
6. Livermore DM, Mushtaq S, Ge Y, Warner M. 2009. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int. J. Antimicrob. Agents 34:402-406. http://dx.doi.org/10.1016/j.ijantimicag.2009.03.021.
7. Moya B, Zamorano L, Juan C, Perez JL, Ge Y, Oliver A. 2010. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob. Agents Chemother. 54:1213-1217. http://dx.doi.org/10.1128/AAC.01104-09.
8. Zamorano L, Juan C, Fernandez-Olmos A, Ge Y, Canton R, Oliver A. 2010. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin. Microbiol. Infect. 16:1482-1487. http://dx.doi.org/10.1111/j.1469-0691.2010.03130.x.
9. Juan C, Zamorano L, Perez JL, Ge Y, Oliver A, Spanish Group for the Study of Pseudomonas, Spanish Network for Research in Infectious Diseases. 2010. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 54:846-851. http://dx.doi.org/10.1128/AAC.00834-09.
10. Craig WA, Andes DR. 2013. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum betalactamases, in the thighs of neutropenic mice. Antimicrob. Agents Chemother. 57:1577-1582. http://dx.doi.org/101.128/AAC.01590-12.
11. Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP. 2012. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrob. Agents Chemother. 56:544-549. http://dx.doi.org/10.1128/AAC.01752-10.
12. Moya B, Zamorano L, Juan C, Ge Y, Oliver A. 2010. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:3933-3937. http://dx.doi.org/10128/AAC.00296-10.
13. Clinical and Laboratory Standards Institute. 2007. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. CLSI document M7-A7. Clinical and Laboratory Standards Institute, Wayne PA.
14. Andes D, Craig WA. 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19:261-268. http://dx.doi.org/10.1016/50924-8579(02)00022-5.
15. Craig WA. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96. http://dx.doi.org/10.1016/0732-8893(95)00053-D.
16. Craig WA, Andes DR. 2008. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob. Agents Chemother. 52:3492-3496. http://dx.doi.org/10.1128/AAC.01273-07.
17. Fantin B, Leggett J, Ebert S, Craig WA. 1991. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob. Agents Chemother. 35: 1413-1422. http://dx.doi.org/10.1128/AAC.35.7.1413.
18. Leggett JE, Fantin B, Ebert S, Totsuka K, Vogelman B, Calame W, Mattie H, Craig WA. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159:281-292. http://dx.doi.org/10.1093/infdis/159.2.281.
19. VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob. Agents Chemother. 57:2809-2814. http://dx.doi.org/10.1128/AAC.02513-12.
20. Muller AE, Punt N, Mouton JW. 2013. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J. Antimicrob. Chemother. 68:900-906. http://dx.doi.org/10.1093/jac/dks468.
21. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP. 2012. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidimeavibactam against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56:6137-6146. http://dx.doi.org/10T128/AAC.00851-12.
22. Ge Y, Whitehouse MJ, Friedland I, Talbot GH. 2010. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob. Agents Chemother. 54:3427-3431. http://dx.doi.org/10.1128/AAC.01753-09.
23. Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. 2012. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob. Agents Chemother. 56:3086-3091. http://dx.doi.org/10.1128/AAC.06349-11.
24. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12. http://dx.doi.org/10.1086/516284.